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A B S T R A C T
Of the 2,635,000 new cancer cases (excluding non-melanoma skin cancers) occurring in the European
Union (EU) in 2012, it is estimated that approximately 185,000 are related to infection with human
papillomaviruses (HPVs), hepatitis B and C viruses (HBV and HCV), and Helicobacter pylori (H. pylori).
Chronic infection with these agents can lead to cancers of the cervix uteri, liver, and stomach,
respectively. Chronic infection with HCV can also lead to B-cell non-Hodgkin lymphoma. Human
immunodeﬁciency virus (HIV) infection continues to be of major public health importance in several EU
countries and increases cancer risk via HIV-induced immunosuppression. The fourth edition of the
European Code Against Cancer presents recommendations on effective and safe preventive interventions
in order to reduce the risk of infection-related cancers in EU citizens. Based on current available
evidence, the fourth edition recommends that parents ensure the participation of their children in
vaccination programs against HBV (for newborns) and HPV (for girls). In the ‘Questions and Answers’
(Q&As) section about vaccination and infections in the website for the European Code Against Cancer,
individuals who are at risk of chronic HBV or HCV are advised to seek medical advice about testing and
obtaining treatment when appropriate. Individuals most at risk of HIV are advised to consult their doctor
or healthcare provider to access counselling and, if needed, testing and treatment without delay.
Information about H. pylori testing and treatment is also provided as testing might currently be offered in
some high-risk areas in Europe. The rationale and supporting evidence for the recommendations on
vaccination in the European Code Against Cancer, and for the main recommendations on vaccination and
infection in the Q&As, are explained in the present review.
ã 2015 International Agency for Research on Cancer; Licensee ELSEVIER Ltd https://creativecommons.
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The population-attributable fraction (PAF) for cancer-related
infections in more highly developed countries has been estimated
to be 7.4% [1]. In 2012, approximately 195,000 of 2,635,222 new
cancer cases (excluding non-melanoma skin cancers) occurring in
the European Union (EU) [2] are estimated to be infection-related
[1]. Human papillomaviruses (HPVs), hepatitis B virus (HBV),
hepatitis C virus (HCV), and Helicobacter pylori (H. pylori) account
for approximately 95% of these cases [1]. Because of the
immunosuppression induced by human immunodeﬁciency virus
(HIV), this virus should be also considered a cause of infection-
related cancers in the EU. Current available evidence has been
reviewed here to recommend – in the fourth edition of the
European Code Against Cancer and related ‘Questions and https://creativecommons.org/licenses/by-nc-nd/3.0/igo/
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reduce their risk of infection-related cancers.
2. Human papillomaviruses
2.1. Role in cancer
Twelve HPV types – HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
and 59 – were classiﬁed by the International Agency for Research
on Cancer (IARC) Monographs Program as Group 1 (i.e., ﬁrmly
established) human carcinogens, and a few other types were
classiﬁed as probably or possibly carcinogenic [3]. Cancers caused
by HPV include all cancers of the cervix, most anal cancers (88%),
and less well identiﬁed portions of vaginal (70%), vulvar (43%),
penile (50%), and oropharyngeal cancers (26%) [1,4]. HPV16 and
18 account together for about 70% of cervical cancers in every
world region [5]. In HPV-positive cancers of other anatomical sites,
HPV16 is also the most common HPV type, being found in about
60% of vaginal [6], 80% of anal [7], 60% of penile [8] and 95% of
oropharyngeal [9] cancers. HPV6 and 11 have been classiﬁed as
Group 3 agents (i.e. “not classiﬁable as to its carcinogenicity to
humans”) by the IARC Monographs Program, but are responsible
for almost 100% of genital warts and recurrent respiratory
papillomatosis [3,10].
The natural history and molecular mechanisms involved in
cervical carcinogenesis are well understood [10,11], and effective
screening methods exist to detect precancerous lesions of the
cervix (see Armaroli et al., 2015). HPV is considered a necessary
cause of cervical cancer [3]. Cervical HPV infection is primarily
transmitted by mucosal contact, usually during sexual intercourse.
It is very common in young women after the onset of sexual
activity, with peak prevalence among women under 25 years of age
[11–13]. The majority of HPV infections, often associated with
minor epithelial abnormalities, clear spontaneously within a few
years [12,13]. Persistent HPV infection may lead to precancerous
lesions – cervical intraepithelial neoplasia (CIN) 2 and 3 – around
the mean age of 35–42 years, a proportion of which will progress, if
not treated, to invasive cervical cancer over a period of 10–20 years
[11–13]. The risk for persistence and progression to cancer
precursor lesions varies by HPV type, host factors and the presence
of cofactors [12,13]. Cofactors include smoking, immunosuppres-
sion, high parity and hormonal contraceptive use [3,14–16]. By
speciﬁcally targeting women at the age of risk of developing
CIN 2/3 and cervical cancers, well-organized cervical cancer
screening programs have been able to prevent four out of ﬁve
cervical cancers [17] (Armaroli et al., 2015).
Compared to other HPV-related cancers, cervical cancer is the
most common [4]. It is the fourth most common cancer in women
worldwide, with an estimated 528,000 new cases and
266,000 deaths in 2012, of which 87% occurred in the more
poorly developed regions [18]. The estimated age-standardized
mortality rate (ASMR) ranged from about 2/100,000 in developed
regions (such as Western Europe1) to more than 20/100,000 in
some less developed regions [18].
Cytology-based cervical cancer screening has resulted in a
substantial reduction in cervical cancer incidence in the EU, with
an age-standardized incidence rate (ASIR) in 2012 of 9.6/100,000
(33,679 new cases and 13,136 deaths). However, important1 As deﬁned by the WHO, countries in Western Europe include: Andorra, Austria,
Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy,
Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Spain,
Sweden, Switzerland, and the United Kingdom. Countries in Central Europe include:
Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Hungary,
Former Yugoslav Republic of Macedonia, Montenegro, Poland, Romania, Serbia,
Slovakia, Slovenia and Turkey.regional disparities still exist, with high rates in Central and
Eastern countries of the EU (ASIR 28.6 in Romania, 26.1 in
Lithuania, 24.5 in Bulgaria, 16.1 in Slovakia and 12.2 in Poland)
compared to other EU countries where the estimated ASIR was 10.6
(Denmark) or lower (Fig. 1) [18]. Mortality rates follow a similar
pattern (Fig. 1) [18].
2.2. HPV vaccines
2.2.1. Scientiﬁc justiﬁcation of the European Code Against Cancer
recommendation
2.2.1.1. Efﬁcacy and safety of HPV vaccines. Two prophylactic
vaccines against HPV are currently marketed internationally and in
the EU/European Economic Area (EEA) (which as of July
2013 includes EU-28 and Iceland, Lichtenstein and Norway);
these include the bivalent vaccine produced by GlaxoSmithKline
(Cervarix1), and the quadrivalent vaccine produced by Merck
(Gardasil1), both of which originally had a three-dose schedule for
girls (see below).
The two vaccines are based on virus-like particles (VLPs)
produced by expression in insect cells (bivalent vaccine) or yeast
(quadrivalent vaccine) of the HPV L1 gene, encoding the main
component of the viral capsid. These VLPs are not infectious but are
highly antigenic: they produce a strong antibody response that
prevents infection by neutralizing infectious virions in the mucosa
at the time of contagion [19]. The bivalent vaccine includes
HPV16 and 18 VLPs and is produced with a complex adjuvant
system (ASO4) consisting of monophosphoryl lipid A and alum.
The quadrivalent vaccine, produced with alum adjuvant, includes
HPV16 and 18 VLPs and also HPV6 and 11 VLPs.
For the ﬁrst time in 2009, the World Health Organization
(WHO) recommended the introduction of HPV vaccination into
national immunization programs, targeting 9–13-year-old girls
(i.e. before the onset of sexual activity) with a three-dose regimen
[20]. Evidence available up to September 2008 from the three main
randomized controlled trials (RCTs) at that time (i.e. FUTURE 1 and
FUTURE 2 for the quadrivalent vaccine; PATRICIA for the bivalent
vaccine) and immunobridging studies were used to support this
recommendation. Immunogenicity studies showing that antibody
response to the two licensed vaccines is stronger in adolescent girls
(aged 10–14 years) than in young adult women (aged 15–25 years)
[21–23] permitted bridging of efﬁcacy data to adolescent girls.
Recently, WHO updated its HPV vaccines position paper [24] to
recommend a two-dose regimen with increased ﬂexibility in the
interval between doses (see below).
The evidence on HPV vaccination was updated in the European
Code Against Cancer using the methodology described in greater
detail in this issue (see Minozzi et al., 2015). The Medline, Embase,
PsycINFO and Cochrane Library databases were searched to
identify systematic reviews (SRs) on the efﬁcacy and safety of
HPV vaccines in women; two SRs were selected [25,26]. Additional
scientiﬁc publications identiﬁed by the experts were also included
(as detailed below) to complete the evidence. Due to the relatively
low number of RCTs on efﬁcacy and safety of HPV vaccines in men,
individual studies on this topic were directly searched using the
Cochrane Central Register of Controlled Trials (CENTRAL), and six
articles [27–32] were selected from the publications retrieved.
In women, the totality of the evidence reviewed is in line with
the WHO recommendation with regard to both efﬁcacy and safety;
both vaccines were shown to be safe, generally well tolerated, and
almost 100% effective in preventing persistent cervical HPV16/
18 infections and associated precancerous lesions – CIN2 or 3 (CIN2
+) and adenocarcinoma in situ (AIS) – among young women (mean
age of approximately 20–22 years) not previously infected at the
time of vaccination [25,33–37]. No results from longitudinal
Fig. 1. Estimates of cervical cancer incidence and mortality in the 28 member states of the European Union. Age-standardized rates (ASR) in 2012, adjusted to the World
standardized population (W). Adapted from Ferlay et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France:
International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr (accessed on 26.03.2015).
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on cervical or other cancers.
The vaccines were also shown to prevent infections and CIN1+
in women >25 and 45 years [38–40] who are naïve to the vaccine-
related HPV types, but the frequency of CIN2/3 was much lower in
this age group than among younger women.
In non-cervical sites, the quadrivalent vaccine has been shown
to prevent the majority of vulvar and vaginal HPV infections and
lesions associated with HPV16 and 18, as well as genital warts
caused by HPV6 and 11, as reviewed recently [19]. The bivalent
vaccine has been shown to prevent anal, oral and vulvar HPV16/
18 infections in young women [41–43].
Both vaccines also afford limited protection against non-
vaccine HPV types phylogenetically related to HPV16 and 18. A
6-month cross-protection has been reported against
HPV31 persistent infection for the quadrivalent vaccine and
against HPV31, 33, 45 and 51 persistent infections for the bivalent
vaccine among HPV-naïve women [25,26,35,44,45]. Efﬁcacy
against persistent infections with types 31 and 45 seemed to
decrease in bivalent vaccine trials with increased follow-up [26],
suggesting a waning of cross-protection over time. The signiﬁcance
of early protection against these additional types is not clear and
needs to be monitored over the long term.
Among young men (16–26 years of age) naïve to vaccine-related
HPV types, the quadrivalent vaccine has been shown to prevent
persistent anogenital infection with HPV vaccine types, external
genital lesions including penile, perianal, or perineal intraepithe-
lial lesions, including genital warts [28]. The quadrivalent vaccine
has been demonstrated to prevent anal intraepithelial neoplasia
among men who have sex with men [30]. The quadrivalent and
bivalent HPV vaccines were highly immunogenic for all vaccinetypes [27,31]. RCT results and immunobridging studies [22,27,31]
strongly suggest that, as in women, it would be more effective to
vaccinate young men before they become sexually active.
RCTs conducted essentially prior to vaccine licensure provide
evidence of an excellent safety proﬁle for both vaccines [27–29]
(reviewed in [46]). Pooled analysis of safety data from the
quadrivalent vaccine RCTs [47] or the bivalent vaccine [48] showed
no signiﬁcant difference between the vaccinated and the control
group in terms of occurrence of serious adverse events or deaths.
Further data are also available from passive and active post-
licensure safety surveillance of HPV vaccines. This is an important
component of the overall safety assessment of vaccines, as rare or
unexpected adverse events can be detected which may not have
been evident in clinical trials due to their limited sample size.
Passive surveillance activities are designed to systematically
collect post-vaccination adverse events [49,50]. For HPV vaccines,
the minor adverse events most commonly reported through
passive surveillance are injection site reactions, headache and
dizziness [46,51,52]. Moreover, while a variety of serious outcomes
and deaths have been reported, none has been attributed to the
vaccines [46].
Active surveillance activities involve population-based post-
licensure clinical studies [49]. Concerns have been raised that HPV
vaccines might be associated with such adverse events as
miscarriages, syncope, anaphylaxis, venous thromboembolism
and autoimmune diseases such as multiple sclerosis, cerebral
vasculitis, Guillain–Barré syndrome or chronic pain conditions, but
these safety outcomes have been evaluated in population-based
studies and, to date, no association between HPV vaccines and such
conditions has been identiﬁed [46,51]. These results have been
corroborated by reviews of safety data conducted by a number
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which reviewed data on quadrivalent vaccine safety in 2011 [53],
and the WHO Global Advisory Committee on Vaccine Safety
(GACVS) which has repeatedly reviewed data on both HPV
vaccines, most recently in March 2014 [54]. The GACVS
Committee has remained reassured by the safety proﬁle of the
HPV vaccines, and noted the importance of continued surveil-
lance and epidemiological investigation with an emphasis on the
collection of high-quality data. Such data are essential for
interpretation of any adverse events which may occur following
HPV vaccination. As highlighted in their 2014 report, interpreta-
tion requires due diligence and great care; allegations of harm
being raised on the basis on “anecdotal observations and reports
in the absence of biological or epidemiological substantiation”
may lead to unacceptable harm when “as a result, safe and
effective vaccines cease to be used” [54]. As an example of such
harm, the media coverage of adverse events of HPV vaccines in
November 2013 in France raised concerns about HPV vaccine
safety, and had a negative impact on vaccination coverage; the
proportion of mothers who did not wish to vaccinate their girls
increased signiﬁcantly after November 2013: 23% in September–
November versus 35% in December 2013 [55].
2.2.1.2. Duration of protection: long-term effect and
effectiveness. The longest duration of efﬁcacy of the vaccines
reported to date is approximately 8–10 years for a three-dose
vaccine schedule [56]. Studies – including linkage to cancer
registries – are ongoing to monitor the population impact of HPV
vaccination. Cross-sectional studies of women aged 18–24 years
who received Pap screening in family planning clinics throughout
Australia showed a 77% decrease in prevalence of HPV types
targeted by the quadrivalent vaccine from the period before
(2005–2007) to the period after the vaccine was widely
implemented (2009–2010) [57]. The impact of HPV vaccination
on the incidence of genital warts has been reported also for
Australia [58,59] and recently for Sweden [60], showing a dramatic
reduction in the incidence of genital warts in the HPV-vaccinated
cohorts. It will probably be possible to determine the attributable
reduction in the incidence of cervical and other HPV-related
cancers only after several decades.
HPV vaccination does not eliminate the need for effective
cervical cancer screening in the HPV-vaccinated cohorts (Armaroli
et al., 2015), mainly because the vaccines do not protect against all
oncogenic HPV types. However, vaccination has the potential to
greatly decrease the intensity, cost, and morbidity associated with
screening, and in the future the impact on screening may be even
greater; the FDA has in December 2014 approved the HPV9-valent
vaccine (Merck, Gardasil 9), which is produced using the same
technology and adjuvant as the quadrivalent vaccine and includes
HPV16, 18, 6, 11, 31, 33, 45, 52 and 58 VLPs [61]. Sanoﬁ Pasteur has
recently (June 2015) received approval from the European
Medicines Agency (EMA) for marketing Gardasil 9 in the EU
[62]. This vaccine has the potential to prevent approximately 90%
of cervical, vulvar, vaginal and anal cancers in women caused by
the vaccine HPV types.
By speciﬁcally targeting young girls for vaccination before HPV
infection, and women for screening at the age of risk of
developing cervical cancers, these two strategies have the
potential to yield a greater beneﬁt when implemented together
rather than separately; however, their implementation should be
coordinated in a comprehensive cervical cancer prevention
program [63].
2.2.1.3. Number of doses. A study nested in the Costa Rica vaccine
trial was the ﬁrst to suggest the efﬁcacy of fewer than the
recommended three doses of the bivalent HPV vaccine: at 4 yearsof follow-up, no signiﬁcant difference in efﬁcacy against HPV16/
18 persistent infection was observed when one or two doses of
vaccine were administered, compared to the recommended three-
dose protocol [64]. In addition, several studies have shown that the
immunogenicity of two doses of both vaccines, particularly among
girls aged 9–14 years and when the doses are separated by
6 months, is not inferior to that of three doses among women aged
15–25/26 years, for which vaccine efﬁcacy has been proven [65,66].
The Strategic Advisory Group of Experts (SAGE) on immunization
for the WHO has recently reviewed the evidence related to HPV
vaccination schedules for both bivalent and quadrivalent vaccines.
Results from a systematic review comparing the effects of two-
dose and three-dose HPV vaccination [67] were the basis for the
WHO’s recommendation of a two-dose vaccination schedule with
a 6-month interval for both the bivalent and the quadrivalent
vaccines if administered before age 15. There is no maximum
recommended interval between doses, but if the interval between
doses is shorter than 5 months a third dose is recommended at
least 6 months after the ﬁrst dose. The WHO also recommends
prioritizing vaccination of the primary target population of young
girls 9–13 years of age (for full details of the WHO position see
[24]).
2.2.1.4. State of HPV vaccination in Europe. As of early 2014,
21 countries (Austria, Belgium, Bulgaria, Czech Republic, Denmark,
Finland, France, Germany, Greece, Ireland, Italy, Latvia,
Luxembourg, Malta, the Netherlands, Portugal, Romania,
Slovenia, Spain, Sweden and the United Kingdom) of the 28 EU
Member States have included HPV vaccination in their national
immunization schedules [68,69]. The age group targeted by these
programs varies from one country to another, but it commonly
includes 11–13-year-old girls [68,69]. Currently available data on
three-dose HPV vaccination coverage in the EU indicate that
coverage varies widely between countries and is rarely optimal; for
example, coverage is low in Luxembourg (17%) and France (29%),
medium in Italy (66%) and in the Netherlands (56%), and high in
some countries such as the United Kingdom (80%) and Portugal
(81%) [68]. Variance in coverage across the EU can be explained by
different vaccine implementation policies and/or different
reporting systems [69,70]. Modelling suggests that additional
implementation of catch-up vaccination for girls older than the
primary target population may not enhance the long-term
population effectiveness of vaccination against HPV16/
18 infection. It may, however, shorten the period within which
population effectiveness is reached by 2–5 years [71]. Of the 21 EU
countries mentioned above, 11 (Belgium, Denmark, Finland,
France, Italy, Luxembourg, the Netherlands, Portugal, Romania,
Sweden and the United Kingdom) have also introduced catch-up
programs. In several of these 11 countries, catch-up is offered to
girls and women aged around 14–18 years who have not previously
been vaccinated [68].
The EMA has also granted marketing authorizations for
Cervarix1 and Gardasil1 in the EU/EEA for a two-dose schedule
administered by injection at a 6-month interval for girls aged 9–
14 and 9–13 years respectively. If the respective vaccines are
administered at an older age, the three-dose schedule should be
used (for full details see [72,73]). Some countries, such as France
and the UK, have already implemented a two-dose HPV vaccina-
tion policy. With the exception of Austria [74], vaccinating mid-
adult women (>26 years) is not routinely practiced in the national
immunization programs; the cost-beneﬁt ratio in this age range is
reduced, in part because of the lower incidence of lesions among
women infected by HPV later in life and the lower risk of
progression of these lesions [75,76].
Based on results from RCTs and immunobridging studies, the
national advisory committees on immunization in Australia [77],
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vaccination of young men in routine vaccination schedules. Except
in Austria [74], vaccination of boys is not currently offered in any
public health vaccination program in the EU, as it has not been
shown to be cost-effective because of the much lower burden of
HPV-related cancers in men compared to women [80]. It is worthy
of note, however, that modelling studies suggest that vaccination
of boys might impact on cervical cancer burden by reducing HPV
circulation in women, especially if high vaccine coverage is not
achieved in girls [71]. However, HPV models are being reassessed
at the moment in some EU countries to take into account new
assumptions: i.e. the new two-dose vaccination schedule and price
reduction of HPV vaccines. Some EU countries may include
adolescent males and/or men in their current HPV vaccination
programs in a near future.Box 1. European Code Against Cancer.
12 ways to reduce your cancer risk
1. Do not smoke. Do not use any form of tobacco.
2.Make your home smoke free. Support smoke-free
policies in your workplace.
3. Take action to be a healthy body weight.
4.Be physically active in everyday life. Limit the time you
spend sitting.
5. Have a healthy diet:
 Eat plenty of whole grains, pulses, vegetables and
fruits.
 Limit high-calorie foods (foods high in sugar or fat)
and avoid sugary drinks.
 Avoid processed meat; limit red meat and foods high
in salt.
6.If you drink alcohol of any type, limit your intake. Not
drinking alcohol is better for cancer prevention.
7.Avoid too much sun, especially for children. Use sun
protection. Do not use sunbeds.
8.In the workplace, protect yourself against cancer-
causing substances by following health and safety
instructions.
9.Find out if you are exposed to radiation from naturally
high radon levels in your home. Take action to reduce
high radon levels.
10. For women:
 Breastfeeding reduces the mother’s cancer risk. If you
can, breastfeed your baby.
 Hormone replacement therapy (HRT) increases the
risk of certain cancers. Limit use of HRT.
11. Ensure your children take part in vaccination pro-
grammes for:
 Hepatitis B (for newborns)
 Human papillomavirus (HPV) (for girls).
12. Take part in organized cancer screening programmes
for:
 Bowel cancer (men and women)
 Breast cancer (women)
 Cervical cancer (women).
The European Code Against Cancer focuses on actions
that individual citizens can take to help prevent cancer.
Successful cancer prevention requires these individual
actions to be supported by governmental policies and
actions.2.2.2. Key points for the general public, healthcare providers and
health policy makers
 Based on the above evidence, the European Code Against Cancer
recommends (to parents): “Ensure your children take part in
vaccination programs for human papillomavirus (HPV) (for
girls)” (Box 1, no.11).
In the questions and answers (Q&As) dealing with vaccination
and infections on the European Code Against Cancer website [81],
the Working Group on Infections and Vaccination in the European
Code Against Cancer project provides additional information that
would be of particular relevance for parents, boys and girls, and
young women interested in learning more about what they could
do to lower the risk of cancer from HPV infection. Key messages
include:
 WHO recommends HPV vaccination for girls aged 9–13. This is
because sexual activity usually begins at later ages, and most
girls (9–13 years old) are therefore unlikely to have already been
infected.
 HPV vaccination is highly effective in boys but is currently
offered in only one public health program in the European Union.
At the moment, parents can choose to have their adolescent sons
vaccinated at their own expense in consultation with their doctor
or healthcare provider.
 The current vaccines are highly effective in preventing infections
with HPV types 16 and 18, the types that cause most cervical and
anal cancers, but they do not prevent infection with all the types
of HPV that may cause cancer. It is very important to remember
that vaccination will profoundly diminish screening intensity
but vaccinated women will still need to participate in cervical
cancer screening.
3. Hepatitis B and hepatitis C viruses
3.1. Role in cancer
HBV and HCV target the liver and replicate in hepatocytes. They
have been classiﬁed by the IARC Monographs Program as Group 1
human carcinogens [3], and chronic HBV and/or HCV infection are
the most important causes of hepatocellular carcinoma (HCC)
worldwide with an estimated PAF of 77% [82–84]. People who
become chronically infected with HBV and/or HCV (also known as
carriers) are at higher risk of developing chronic liver disease,
progressing from chronic hepatitis to ﬁbrosis, cirrhosis, and ﬁnally
HCC. Hepatitis B or C carriers generally have no noticeable
symptoms until the liver has been signiﬁcantly damaged. Cirrhosis
can be considered a pre-cancerous stage, being found in 80–90% of
patients with HCC [85]. Chronic HCV infection is also a risk factor
for B-cell non-Hodgkin lymphoma (NHL) [3]. Direct HCV infection
of B cells may be involved in this oncogenic process as peripheral-
blood B cells from HCV carriers have been shown to be infected
with HCV [86]. However, HCV-associated NHL is rare, with an
estimated PAF of 8% worldwide [82].
HCC represents approximately 80–85% of primary liver cancers
(PLCs) globally. PLC, roughly equivalent to rates of HCC, is
predominant in men, being the ﬁfth most common cancer in that
gender (554,000 cases in 2012, 7.5% of total cancer cases
worldwide) and the ninth most common in women (228,000
cases in 2012, 3.4% of total cases) [18]. On account of high lethality,
HCC is the second most common cause of death from cancer
worldwide (746,000 deaths in 2012, 9.1% of total deaths) [18]. Most
of the burden of HCC is conﬁned to developing countries; in 2012,
83% of new cases occurred in less developed regions. The regions of
high incidence are Eastern and South-Eastern Asia (ASIR of 31.9/
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and Western Africa (10.2 and 8.1, respectively) for women [18]. In
the EU, by contrast, estimated incidence rates in men are low in the
North (AISR of 2.4 and 4.6/100000, respectively, in the Netherlands
and the UK) and intermediate in the South (Italy: 11; Portugal: 8.6;
Spain: 9.9); some EU countries in the West and East – such as
France (11.3), Luxembourg (10.3) and Romania (9.2) – also have
intermediate rates (Fig. 2) [18]. For women in the EU, the estimated
ASIR ranges from 0.9 in the Netherlands to 3.6 in Italy [18]. Given
the very poor prognosis of liver cancer, the geographical patterns of
HCC incidence and mortality are quite similar [18].
Worldwide, the relative contributions of the major risk factors
for HCC – i.e. HBV and/or HCV chronic infection, consumption
of aﬂatoxin-contaminated maize and groundnuts, and heavy
alcohol consumption – vary by geographic region [83,84].
Alcohol-associated liver cirrhosis (Scoccianti et al., 2015) is the
most important risk factor for HCC in populations with low
prevalence of HBV and HCV, as in the United States and Northern
Europe [84,87]. Aﬂatoxin exposure is a major risk factor in East
and Southeast Asia and in sub-Saharan Africa, where regulatory
control is weak [84]. In areas where chronic HBV or HCV infection
endemicity is high – hepatitis B surface antigen (HBsAg)
prevalence 8% and anti-HCV >3.5% respectively – chronic HBV
and/or HCV infection is a major risk factor for HCC [83]. The
prevalence of chronic HBV infection is highest (HBsAG prevalence
8%) in Southeast Asia, China and sub-Saharan Africa and is also
high in the southern parts of Eastern and Central Europe.
Prevalence of chronic HCV infection is highest (anti-HCV 10%)
in Pakistan, Egypt, and Mongolia, and is also high in some parts of
China, Italy and Japan [84].Fig. 2. Estimates of liver cancer incidence in men in the 28 member states of the Europe
population (W). Adapted from Ferlay et al. GLOBOCAN 2012 v1.0, Cancer Incidence and M
Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr (accessed onIn Europe, as observed worldwide, when comparing one
geographic region to another, the contribution of chronic HBV/
HCV infection to the etiology of HCC varies between countries [88].
This variation is linked to the prevalence of chronic HBV/HCV
infection, which varies widely between the countries in the
European Union/European Free Trade Association (EU/EFTA) (as of
July 2013: EU-28 and Iceland, Lichtenstein, Norway and Switze-
land) [89]. Some countries, such as the Northern countries and the
UK, can be considered at low risk for chronic HCV or/and HBV
infection (estimated prevalences <1%) and at lower risk for
infection-related HCC (Fig. 3) [88,89]. For example, in Sweden
about 15% of HCC cases are anti-HCV+ and 3% are HBsAg+, while 82%
are negative for both viruses. In Belgium and the UK about 25% are
anti-HCV+ and 20% are HBsAg+, while 45% are negative and 10%
positive for both viruses [88,89]. High-risk countries for chronic
HBV infection are Greece (estimated prevalence 2.1%) and Romania
(5.6%); in Greece about 56% of HCCs are HBsAg+ and 16% are anti-
HCV+, while 25% are negative and 3% positive for both viruses
(Fig. 3) [88,89]. High-risk countries for chronic HCV infection are
South Italy (i.e. Sicily: 10.4%) and Romania (3.5%) (Fig. 3) [88,89].
In the EU/EFTA region, about 4.5 million (HBV) and 5.5 million
(HCV) adults are carriers [90]. These ﬁgures are likely under-
estimates; most hepatitis B or hepatitis C carriers are currently
undiagnosed as chronic infection is usually asymptomatic until the
late stages of liver damage. Moreover, people at high risk of being
carriers, such as migrant groups from endemic countries and
elderly people, are generally under-represented in the statistics.
Reported data suggest that the prevalence of chronic HBV and/or
HCV infections is higher in migrants from endemic countries than
in the general population in the EU/EFTA [91]. In some Southern
European countries like Italy, Spain and Portugal, the burden ofan Union. Age-standardized rates (ASR) in 2012, adjusted to the World standardized
ortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International
 26.03.2015).
Fig. 3. Hepatitis B and hepatitis C prevalence (%) in the general population by country in Europe, 2000–2009. (a) Hepatitis B surface antigen (HBsAg) prevalence (%). (b)
Hepatitis C (anti-HCV antibody) prevalence (%). From Hahné et al. BMC Infectious Diseases 2013, 13:181 available at http://www.biomedcentral.com/1471-2334/13/181.
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ageing unvaccinated population (hepatitis B) and to injecting drug
use (hepatitis C) [92].
3.1.1. Hepatitis B virus
HBV is a DNA virus transmitted by exposure to infected blood
and other body ﬂuids, including semen and vaginal ﬂuids. Around
the time of birth, HBV is transmitted to babies by carrier mothers,
and this is the main route of transmission in highly endemic
regions. During childhood, transmission can occur between
children living in close proximity, although the exact route is
unclear. In adult life, the virus can spread through sexual contact or
by use of contaminated needles. The age of infection is critically
important in determining whether the infection can become
chronic [84]; HBV-infected newborns have an 80–90% probability
of developing chronic infection; children infected in the ﬁrst
5 years of life have a 20–50% probability of becoming carriers,
while those infected in adult life have a probability of <10% of
developing chronic infection. Conversely, the risk of developing
acute hepatitis, ranging from no symptoms at all to severe illness
(fever, jaundice and lethargy), is approximately one third in adult
infections, but rare in children [84].
Chronic infection is characterized by serum persistence
(>6 months) of HBsAg. The risk of progression to liver disease is
associated with active HBV replication, determined by tests for
HBeAg and levels of HBV DNA [85]. There are various mechanisms
by which HBV may promote carcinogenesis: (1) integration of HBV
DNA into the host genome that alters the function of endogenous
genes or induces chromosomal instability; (2) accumulation of
genetic damage due to hepatic inﬂammation mediated by virus-
speciﬁc T cells; and (3) induction of oxidative stress by expression
of viral proteins HBx and HBs [93].
3.1.2. Hepatitis C virus
HCV is an RNA virus with a highly variable genome. The
distribution of HCV genotypes and sub-genotypes depends on the
geographic region, and in Europe HCV1b is the main one [94]. HCV
infection occurs mainly from contaminated blood or blood
products. Before the 1990s, when widespread screening of the
blood supply for HCV contamination began in developed countries,
hepatitis C was commonly spread through blood transfusions and
blood products. The risk of HCV transmission through donated
blood is now very small in Europe and most developed countries,
and most new infections with HCV occur by sharing needles or
other equipment to inject drugs. Diagnostic procedures and
treatments in healthcare facilities with inadequate infection
control practices may also be a source of infection. This is the
reason why hepatitis C epidemics can be concentrated in certain
high-risk populations, for example among people who inject drugs
and/or in general populations in certain areas. More rarely, HCV
can also be acquired from sexual and household contacts [84]. HCV
infection can be both acute and chronic. Unlike HBV, the risk of
chronic infection with HCV does not decrease when infection
occurs in adults. About 15% of those initially infected will develop
acute hepatitis which is generally asymptomatic, and spontane-
ously clear the virus. The remaining 85% will become carriers [95].
Chronic infection is characterized by serum persistence
(>6 months) of HCV RNA and HCV antibodies [96]. Approximately
20% of HCV carriers will develop HCC by the age of 75 years [97].
3.2. Interventions
3.2.1. Hepatitis B virus vaccines
3.2.1.1. Scientiﬁc justiﬁcation of the European Code Against Cancer
recommendation. The most effective intervention againstinfection with HBV is primary prevention through vaccination.
There is no vaccine available against HCV infection. Hepatitis B
vaccines are composed of highly puriﬁed preparations of HBsAg.
The ﬁrst vaccines, available in 1982, were plasma-derived. Since
1986, these vaccines have been replaced by recombinant hepatitis
B vaccine, which is obtained by expressing HBsAg in yeast or
mammalian cells. Aluminum phosphate or aluminum hydroxide is
used as an adjuvant. Hepatitis B vaccine is available as monovalent
formulations or in ﬁxed combination with other vaccines,
including diphtheria–tetanus–pertussis (DTP), Haemophilus
inﬂuenzae type b, hepatitis A, and inactivated polio.
Since 1997, WHO has recommended hepatitis B vaccination for
all newborns, and the last updated position paper was published in
2009 [98]. The WHO recommended that all infants receive the
hepatitis B vaccine (monovalent) as soon as possible after birth,
preferably within 24 h, independently of whether the country has
high, medium or low endemicity; two or three additional
monovalent or combined vaccine doses – at 1 and 6 months of
age in most countries – are given in addition to the birth dose to
complete immunization.
The evidence on efﬁcacy and safety of HBV vaccination was
updated with a systematic search of the Medline, Embase,
PsycINFO and Cochrane Library databases up to January 2013;
two SRs [99,100] were selected based on the European Code
Against Cancer methodology. Neither of these reviews reported
chronic hepatitis B, liver cirrhosis or HCC incidence or mortality
outcomes but reported either anti-HB level [99] or occurrence of
hepatitis B infection [100]. Ortqvist’s SR [99] showed efﬁcacy, but
no meta-analysis was performed. Mathew’s SR [100] showed
contradictory results on efﬁcacy depending on the method used to
perform data analysis. The evidence available since the last WHO
position paper is therefore summarized below using individual
studies.
Effectiveness studies have been performed in highly HBV
endemic countries or regions with high rates of HCC. Surveys on
seroprevalence of HBsAg in children carried out before and after
introduction of immunization programs show a signiﬁcant
reduction in the rate of chronic infection among immunized
children. In China, where the immunization program was
introduced in 1992, the prevalence of HBsAg positivity in children
younger than 5 years decreased from 9.7% in 1992 to 1.0% in 2006
[101]. In Taiwan, since implementation of vaccination in 1984,
seroprevalence in children decreased from 10% in 1984 to 0.9% in
2009 [102]. Comparison of vaccinated birth cohorts with
unvaccinated ones in studies with 25–30 years of follow-up time
have shown the effectiveness of hepatitis B immunization in
lowering mortality from fulminant hepatitis and incidence of HCC
in Taiwan [103], Qidong City (China) [104], Japan [105], and Alaska
[106]. The studies’ results are summarized below.
In Taiwan, the birth cohort born in 1981–1984, which received
HBV vaccines at preschool ages instead of early infancy, had
signiﬁcantly lower HCC mortality and incidence than those born in
1977–1980 (RR 0.70, 95%CI 0.59–0.83 of HCC mortality; RR 0.73,
95%CI 0.63–0.85 of HCC incidence) [103].
In Qidong City, China, a controlled neonatal HBV vaccination
trial began in 1983 and ended in November 1990. After the end of
the trial, vaccination of newborns continued without interruption.
Compared with 1980–1983, the age-speciﬁc liver cancer incidence
rates in 2005–2008 signiﬁcantly decreased 1.9-fold at ages 0–19,
14-fold at ages 20–24, 9-fold at ages 25–29, 4-fold at ages 30–34,
1.5-fold at ages 35–39, 1.2-fold at ages 40–44 and 1.4-fold at ages
45–49, but increased at older ages. The reduction at ages below
25 reﬂect the combined effects of interventions to reduce aﬂatoxin
exposure and neonatal HBV vaccination [104].
A nationwide prevention program utilizing immunoprophy-
laxis for high-risk newborn babies against maternal HBV
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of patients with HBV-positive HCC and the ratio of HBV-positive
HCC to hepatoblastoma decreased over the study period. There
was a signiﬁcant decrease in HBV-positive HCC during the last
study periods (2001–2008) compared with HBV-negative HCC
(P < 0.001) [105].
A universal newborn immunization with hepatitis B
vaccine was initiated in 1984 among Alaskan native people;
the incidence of HCC in persons below 20 years of age
decreased from 3/100,000 in 1984–1988 to zero in 1995–1999,
and no cases have occurred since 1999 (test for trend overall,
P < 0.001) [106].
Only two RCTs initiated during the 1980s examine HCC as an
outcome. They were conducted in areas where the high incidence
of liver cancer was attributable to endemic HBV infection, but also
to dietary exposure to aﬂatoxin. The Gambian Hepatitis Interven-
tion Study (GHIS) was conducted from 1986 to 1990 in Gambia
(Africa) [107]; 24 years after vaccination, vaccine efﬁcacy against
chronic infection with hepatitis B virus was 95.1% (95% CI 91.5–
97.1%) [108]. The latest estimates [109] indicate that the
evaluation of the protective efﬁcacy of HBV vaccine against
HCC should be measurable from 2017. The Qidong Hepatitis B
Intervention Study (QHBIS), an RCT of neonatal HBV vaccination,
was conducted between 1983 and 1990 in Qidong County (China)
[110]. This population-based, cluster randomized, controlled trial
included 39,292 newborns who were randomly assigned to the
vaccination group in which 38,366 participants completed the
HBV vaccination series and 34,441 newborns who were randomly
assigned to the control group in which the participants received
neither a vaccine nor a placebo. However, 23,368 (67.8%)
participants in the control group received catch-up vaccination
at age 10–14 years. At 30-year follow-up, the incidence rate of
primary liver cancer (PLC) and the mortality rates of infant
fulminant hepatitis were signiﬁcantly lower in the vaccination
group than in the control group, with a risk reduction estimated
to be 84% (95% CI 23–97%) and 60% (95% CI 34–86%) respectively
[111]. The estimated efﬁcacy of catch-up vaccination on
HBsAg seroprevalence in early adulthood was substantially
weaker than that of the neonatal vaccination. Limitations of
the study results include the small number of individuals with
PLC, the large number of participants lost to follow-up, and the
large proportion of participants who did not provide serum
samples at follow-up.
Since its availability in 1982, more than 1 billion doses of HBV
vaccine have been used worldwide; so far no serious safety
concerns regarding the HBV vaccines have been reported by any
national or international (i.e. Global Alliance for Vaccines and
Immunization, GAVI) surveillance system authority. No safety
concern was highlighted either through exhaustive review of
scientiﬁc evidence such as the one published in 2013 by the
Institute of Medicine in the USA [112].
In the EU, only four countries (Denmark, Finland, Sweden and
the UK) have not introduced immunization against hepatitis B
into their childhood immunization programs on account of the
historically low prevalence of HBV infection in the general
population. These countries opted instead for systematic high-
coverage surveillance of pregnant women to identify carrier
mothers, and administration of HBV vaccination only to new-
borns whose mother was infected. A survey of hepatitis B
immunization programs was performed in 2008–2009 in 25 EU
members [113]. Based on this survey, of the 20 countries with a
childhood immunization program, 18 countries had the ﬁrst
hepatitis B vaccine dose scheduled at birth or 2–3 months after
birth, and two countries vaccinated only schoolchildren. Of those
18 countries, 11 provided catch-up programs for older children or
teenagers [113].3.2.1.2. Key points for the general public, healthcare providers and
health policy makers..
 Based on the above evidence, the European Code Against Cancer
recommends (to parents): “Ensure your children take part in
vaccination programs for hepatitis B (for newborns)” (Box 1,
no.11).
In the Q&A section [81], the Working Group on Infections and
Vaccination also provided additional information that would be of
particular relevance for parents interested in learning more about
what they could do to lower the risk of liver cancer from hepatitis B
infection (see also Section 3.2.2.3). A point considered by the
Working Group to be particularly relevant is:
 In a few EU countries (the United Kingdom and some Nordic
countries) vaccination against hepatitis B is offered only to high-
risk newborns (i.e. newborns of mothers who are HBV-positive).
However, parents living in one of these countries may wish to
consider having their children vaccinated at their own expense in
consultation with their doctor or other healthcare provider.
3.2.2. The “test and treat” intervention
Because the disease is often asymptomatic and left untreated,
people with chronic HBV and/or HCV infection remain infectious to
others and are themselves at risk of serious liver disease such as
liver cirrhosis or HCC. Various drugs for treatment of chronic HBV
or HCV infection have received marketing authorization approval.
Efﬁcacy and safety of these drugs have been reviewed recently by a
number of recognized advisory bodies to produce the following
evidence-based guidelines or recommendations:
 WHO: guidelines for the screening, care and treatment of people
with hepatitis C infection (2014) [114];
 National Institute for Health and Care Excellence (NICE):
Hepatitis B and C testing: people at risk of infection (2012) [115];
 NICE: hepatitis B (chronic) diagnosis and management (2013)
[116];
 European Association for the Study of the Liver (EASL):
management of chronic hepatitis B infection (2012) [117];
 EASL: recommendations on treatment of hepatitis C (2014)
[118];
 US Preventive Services Task Force (USPSTF): screening for
hepatitis B virus infection in non-pregnant adolescents and
adults (2014) [119].
In summary, these guidelines recommend (1) to offer HBV and
HCV serology testing to individuals from high-risk groups (Table 1);
(2) to assess carriers of HBV and HCV for antiviral treatment (i.e.,
selection of antiviral drugs to be used, duration of treatment, and
subsequent monitoring of patients, genotyping being recom-
mended only for chronic HCV infection); and (3) to offer adequate
treatment to individuals with evidence of active infection or liver
damage. NICE, EASL, and WHO guidelines also provide detailed
recommendations and guidance to health professionals regarding
protocols for treatment of carriers, taking into account patient
assessment (e.g., severity of liver disease; previous treatment
failure, and genotyping for chronic HCV infection). The NICE
recommendations also take into account evidence of cost-
effectiveness. A summary of the evidence regarding efﬁcacy and
safety of the main currently available drugs that are described in
the above guidelines is provided in the following paragraphs.
Speciﬁc recommendations on which treatment to use are not
provided since this was not the aim of European Code Against
Cancer project; treatment depends on patient assessment and the
recommendations in place in a speciﬁc country.
Table 1
Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) carriers: high-risk groups.
Groups at increased risk of being chronic HBV carriersa compared to the general
population
Groups at increased risk of being chronic HCV carriersb compared to the general
population
 People not vaccinated as newborns against HBV and included in one or more of
the categories below
 People who have ever injected drugs
 People born or brought up in a country with an intermediate or high prevalence
(2%) of chronic hepatitis B. This includes all countries in Africa, Asia, the
Caribbean, Central and South America, Eastern and Southern Europe, the Middle
East and the Paciﬁc islands. In the EU, this includes some countries such as Greece
and Romania
 People who received a blood transfusion or blood products before the 1990s
 Recipients of potentially infected blood products or invasive procedures in
healthcare facilities with inadequate infection control practices
 Babies born to mothers who are HBV carriers  People born or brought up in a country with an intermediate or high prevalence
(2%) of chronic hepatitis C. US-born people not vaccinated as infants whose
parents were born in regions with a very high prevalence of HBV infection (8%),
such as sub-Saharan Africa and Central and Southeast Asia. In the EU, this
includes countries such as Italy (particularly Southern Italy and Sicily), and
Romania
 People who have ever injected drugs  Babies born to HCV-infected mothers
 Men who have sex with men  People with HCV-infected sexual partners
 Anyone who has ever had unprotected sex  People with HIV infection
 Anyone (especially babies and children under the age of 10) subject to close
contacts with carriers (i.e. where there is a risk of transmitting the infection
through blood or body ﬂuids). This could include the family members, close
friends, household contacts or sexual partners of someone known to be
chronically infected with hepatitis B
 People born in countries and regions outside the EU with a high prevalence of
HCV infection, such as Eastern and South-Eastern Asia
 Healthcare workers  People who have used intranasal drugs (e.g. through sharing of inhalation
equipment for cocaine)
 People who have had tattoos or piercings
 Healthcare workers
a Adapted from National Institute for Health and Care Excellence 2012 [115].
b Adapted from World Health Organization 2014 [114], National Institute for Health and Care Excellence 2012 [115] and European Association for The Study of the Liver 2014
[118].
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of HBV-related liver disease is associated with HBV DNA levels in
the blood. Unlike HCV treatment, treatments against chronic
hepatitis B can control but do not cure HBV infection, owing to the
persistence of HBV in the hepatocyte genome. Antiviral therapy
suppresses HBV replication, ensuring long-term suppression of the
viral load. This is associated with histological improvement and
reversal of ﬁbrosis and cirrhosis, and thereby the likelihood of
serious clinical disease is reduced [120–123].
Seven antiviral drugs falling into two groups are licensed in
most European countries for treatment of chronic HBV infection:
interferons (interferon alpha, INFa and pegylated (PEG)-INFa), and
oral nucleos(t) ide analog (NA) polymerase inhibitors (lamivudine,
adefovir, entecavir, telbivudine and tenofovir). PEG-INFa, enteca-
vir, and tenofovir are licensed as ﬁrst-line treatments and
recommended as such in most current guidelines [117].
Two SRs show that, compared to no treatment, INFa treatment
signiﬁcantly decreased the incidence of liver cirrhosis, liver cancer
and liver-related death [124,125]. However, in Jin’s [125], the effect
on liver cancer is less signiﬁcant when the Bayesian meta-analysis
approach was used to combine data (RR 0.27, 95% CI 0.06, 1.03)
compared to the Der Simonian–Laird approach (RR 0.47, 95% CI
0.26, 0.85). Compared to the ﬁrst generation of NAs, development
of resistance and relapse after treatment cessation seem to be
signiﬁcantly lower with entecavir and tenofovir [117,126]. No direct
evidence on the efﬁcacy of entecavir/tenofovir in preventing or
delaying HCC is available because these drugs are relatively new,
and HCC development takes several decades. However, indirect
evidence of cancer prevention is available, as reviewed recently
[127,128].3.2.2.2. Chronic hepatitis C treatment available or under
development. Successful eradication of HCV by treatment is
deﬁned as achievement of sustained virological response (SVR),
i.e. absence of viremia 18 or 24 weeks after cessation of all antiviral
medication, which is associated with a reduction of cirrhosis,
incidence reduction of HCC and liver-related death [129–131].
Since the introduction of indirect antiviral drugs, INFa
monotherapy in 1990 and ribavirin (RBV) in combination with
PEG-INFa in 2002, research has focused on developing more
effective antiviral treatments that target HCV directly, are orally
administered, safe and effective across all genotypes, and that
achieve high SVR rates.
In 2011, telaprevir or boceprevir, the ﬁrst generation of
inhibitors of the HCV NS3/4A serine protease, were approved by
regulatory agencies – the US Food and Drug Administration (FDA),
the EMA, and others – for treatment of patients infected with
chronic HCV genotype 1 in a triple-therapy regimen with RBV and
INFa. This treatment has been reported to be more effective than
the combination of RBV and PEG-INFa alone achieving a 60–70%
SVR and a 75% reduced risk of HCC [132]. Unfortunately, this
treatment is associated with more adverse events than the dual
therapy, is expensive, requires several months’ duration, and has a
high pill burden.
Since 2011, a number of new antiviral compounds – such as
simeprevir, sofosbuvir and ledispasvir – has been developed, and
some additional compounds are currently in various stages of
development, including marketing authorization assessment. The
main characteristics of these new products as reported in the
literature are shorter treatment duration, easier administration
protocol (i.e. a single daily oral administration), fewer side effects,
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inhibitors, has been recently licensed as part of a combination
treatment regimen with RBV and PEG-INFa. Evidence has shown
that simeprevir is effective against HCV genotype 1 excluding the
genotype 1a NS3 Q80K polymorphism [133–137]. Sofosbuvir,
inhibitor of the HCV NS5B RNA polymerase, has recently been
approved by the FDA and the EMA, and is effective and safe in
combination with either RBV alone or with RBV and PEG-INFa for
treatment of genotypes 1–6 [138–140]. Inhibitors of the HCV
protein NS5A, such as ledipasvir, have recently been reviewed
[141] and seem to be very promising new treatments. They are
active against all HCV genotypes, require once-daily dosing, and
show resistance proﬁles that do not overlap with those of other
anti-HCV medicines. Marketing authorization application was
made to the FDA and the EMA in February 2014 for a once-daily
ﬁxed-dose combination of ledipasvir with sofosbuvir [142,143].
While the cost of new drugs is currently the major obstacle to their
large-scale use, the manufacturing of these drugs is not per se
expensive, opening the way to rapid price decline particularly in
the public sector use [144]
3.2.2.3. Key points for the general public, healthcare providers and
health policy makers. In the Q&A section [81], based on the above
evidence, the Working Group on Infections and Vaccination in the
European Code Against Cancer project provided further
information that would be of particular relevance for adults
interested in learning more about what they could do to lower the
risk of liver cancer from hepatitis B and C. Key messages include:
 Individuals in high-risk groups for chronic HBV and/or HCV
infection should consult their doctor or other healthcare
provider to get a HBV or HCV test and be advised about
treatment options, if tested positive. Effective treatments are
available that will reduce the risk of developing liver cancer.
 To prevent HCV transmission, individuals are advised to avoid
injections and use oral treatments, when available and possible,
especially when traveling to countries in which medical care is
suboptimal. It is also recommended to avoid body piercing,
tattooing or acupuncture, if there is any doubt about the safety/
hygiene of the procedure. Absence of proper needle handling is
common in countries or regions outside Europe with limited
economic resources and during times of political or social
upheaval.
4. H. pylori
4.1. Role in cancer and situation in Europe
H. pylori was classiﬁed by the IARC Monographs Program as a
Group 1 carcinogen in 1994; this classiﬁcation was maintained in
2009 after more recent evidence was reviewed [3]. Approximately
89% of non-cardia gastric cancer cases, representing 78% of all
gastric cancer cases worldwide, are now estimated to be
attributable to chronic H. pylori infection [145]. Chronic H. pylori
infection can also cause low-grade B-cell MALT gastric lymphoma,
which is rare, representing less than 2% of all gastric cancers [3,82].
Even if the recently observed decline in gastric cancer incidence
rates is assumed to continue, the global burden in 2030 is expected
to remain the same due to demographic change. Gastric cancer is
the ﬁfth most common malignancy in the world, but it is the third
leading cause of death in both sexes, accounting for 8.8% of the
total deaths from cancer worldwide in 2012. The highest mortality
rates were reported in East Asia (ASMR of 24 and 9.8/100,000 for
men and women, respectively) and the lowest in North America
(2.8 and 1.5/100,000 for men and women, respectively) [18].In Europe, gastric cancer incidence varies by region: in 2012,
the estimated ASIR was 11.7/100,000 (for men) and 5.9/100,000
(for women) in Southern Europe, 20.3 (men) and 8.9 (women) in
Central and Eastern Europe, and 7.4 (men) and 3.7 (women) in
Northern Europe [18]. H. pylori prevalence follows a similar
pattern: prevalence of the infection was generally higher in
countries in Southern Europe (e.g. 84.2%, 18–30 years of age, in
Portugal [146], 58.0%, 18–69 years of age, in Italy [147]) and
in Central and Eastern Europe (e.g. 61.7%, <17 years of age, in
Bulgaria [148]) than in Northern European countries (e.g. 11.0%,
25–50 years of age on average in Sweden [148] and 27.6%, 40–49
years of age in the UK [149].
H. pylori infection is strongly associated with socioeconomic
conditions [150], and transmission appears to occur through close
personal contact, particularly within the family [3] and typically in
early childhood. Once established, infection usually persists
throughout life unless it is treated. The prevalence of H. pylori
infection has decreased in recent decades, particularly among
children in developed countries, probably reﬂecting improvements
in hygiene [151,152].
4.2. Intervention: H. pylori eradication
Several randomized trials conducted mainly in high-risk
populations in Asia have produced evidence indicating that H.
pylori eradication reduces the risk of developing gastric precan-
cerous lesions and cancer [153]. In 2012, Ma and colleagues
reported the long-term follow-up results of a randomized trial in
H. pylori-seropositive adults drawn from a general population in
China. By 15 years after randomization the OR of gastric cancer for
H. pylori eradication was 0.61, 95% CI 0.38–0.96 [154]. A meta-
analysis of six randomized trials estimated a relative risk of
stomach cancer as 0.66 (95% CI 0.46–0.95) in asymptomatic
infected individuals [155].
There are treatments available containing combinations of
antibiotics and acid-inhibitors taken for 7–14 days that can safely
eradicate the infection in more than 80% of cases, depending on the
antibiotic resistance patterns of H. pylori within the population
[156].
No screening program for systematically detecting and treating
H. pylori is currently in place because important uncertainties
regarding potential beneﬁts and harms of such programs remain
[157,158]; important questions inherent to the implementation of
any screening programs (e.g. program costs, feasibility, appropriate
target groups for intervention, and to the potential harm of mass
therapy with antibiotics) must ﬁrst be resolved before implement-
ing large-scale programs. In Europe, important data are likely to
emerge from RCTs that are currently in progress or about to begin
in the region. An example is the Gastric Cancer Prevention Study by
Predicting Atrophic Gastritis (GISTAR), which was launched in
2013 in Latvia to evaluate new intervention strategies for gastric
cancer prevention in high-risk areas in East Europe.
5. Human immunodeﬁciency virus
5.1. Role in cancer and situation in Europe
The progression of disease related to human immunodeﬁciency
virus (HIV) is well documented: acute infection stage, clinical
latency, and AIDS (acquired immunodeﬁciency syndrome). AIDS is
a life-threatening condition deﬁned by severe immune dysfunc-
tion.
HIV-positive individuals have an increased cancer risk. Ad-
vanced-stage HIV disease is characterized by immunosuppression,
which is a risk factor for many malignancies [82]. There are three
AIDS-deﬁning cancers: Kaposi sarcoma, NHL, and cervical cancer.
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HIV-infected people are caused by the Epstein–Barr virus [3]. HIV-
infected persons also have elevated risks of other virus-related
cancers – notably anal cancer, hepatocellular carcinoma, and
Hodgkin lymphoma – and a higher prevalence of lifestyle-
associated risk factors, including smoking and alcohol consump-
tion leading to increased risk of cancers of the head, neck and lung
[3]. Overall, the risk of non-AIDS-deﬁning cancers in HIV-infected
people is double that of the general population [159]. Before the
introduction of highly active antiretroviral therapy (HAART) in the
mid-1990s, the life expectancy of people with HIV was severely
compromised. However, the availability of HAART has led to a
striking increase in survival.
At the end of 2011, it was estimated that around 900,000 people
were living with HIV/AIDS in Western and Central Europe 1with an
estimated prevalence of 0.2% in adult population (15–49 years)
[160]. The estimated prevalence in adults was generally higher in
countries from Southern Europe (e.g. 0.7% in Portugal, 0.4% in Italy
and Spain) than in other European countries (e.g. 0.3% in UK, 0.1% in
Finland, Germany, Croatia, Czech Republic and Slovakia; and <0.1%
in Croatia or Czech Republic) [160].
A recent surveillance report prepared jointly by the European
Centre for Disease Prevention and Control (ECDC) and the WHOFig. 4. (a) Rate of reported HIV diagnoses, by year of diagnosis, in the European Union an
mode and year of diagnosis, adjusted for reporting delay, in the EU/EEA (excluding Esto
missing data, i.e., information on the probable source of infection was not available. Fr
Europe: HIV/AIDS surveillance in Europe 2013.Regional Ofﬁce for Europe has pointed out that HIV infection is still
a major public health issue in several countries in the EU/EEA. In
2013, 29,157 new HIV diagnoses were reported in EU/EEA
countries, a rate of 5.7/100,000 population. The countries with
the highest rates of new HIV cases were Estonia (24.6), Latvia
(16.8), Portugal (10.4), Belgium (10.0), Luxemburg (9.9) and the UK
(9.4). The lowest rates were reported in Slovakia (1.5) and Croatia
(2.0) [161]. There are no clear signs of overall decrease in HIV
incidence due to continuing transmission in speciﬁc populations
(Fig. 4) [161]. In 2013, in the EU/EEA region, the majority of new
HIV diagnoses were men who have sex with men (42%) (MSM)
followed by heterosexuals (33%), one third of those being migrants
from countries or areas where there is a generalized HIV epidemic
(i.e. sub-Saharan Africa) [161]. Transmission due to injecting drug
use accounted for 5% of new HIV diagnoses, and transmission
mode was unknown for nearly 20% of new diagnoses [161].
The number of HIV diagnoses among MSM have increased by
33% since 2004 (Fig. 4b) [161]. When information on CD4 cell
counts were reported by countries, nearly half (47%) of all newly
infected individuals had a CD4 cell count <350/mm3, 27% of those
being diagnosed with severe immunosuppression (CD4 <200/
mm3) [161]. This population would have beneﬁted from earlier HIV
testing and HAART treatment (see below).d European Economic Area (EU/EEA). (b) Number of HIV diagnoses, by transmission
nia, Italia, Poland and Spain), 2004–2013. Note that “Other/undetermined” reﬂects
om European Centre for Disease Prevention and Control/WHO Regional, Ofﬁce for
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There is no vaccine to prevent HIV infection and no cure for
chronic infection. Interventions provided to HIV-infected people
include HAART treatment and counselling to reduce high-risk
behaviors.
To evaluate HAART efﬁcacy in preventing cancer in HIV-positive
or AIDS patients, a systematic review was conducted, and
25 primary studies published after 2007 were selected (see
Minozzi et al., 2015). Of these, 19 are retrospective cohort studies
comparing the pre-HAART to the HAART periods. The review
showed that (1) the rate of AIDS-deﬁning cancers (i.e. Kaposi
sarcoma, NHL, and invasive cervical cancer) has continued to fall
since the introduction of HAART, and (2) survival for NHL and
Kaposi sarcoma has increased signiﬁcantly. HAART prevents about
two thirds of the cancers – particularly Kaposi sarcoma and NHL –
in HIV-infected persons [159]. For non-AIDS-deﬁning cancers, the
results are less clear and more conﬂicting: some studies found a
signiﬁcant increase in overall incidence after the introduction of
HAART, whereas others found no signiﬁcant differences between
pre-HAART and HAART periods. The importance of preventing
even moderate levels of HIV-induced immunosuppression is being
increasingly appreciated, notably for the prevention of HPV-
associated cancers [162].
Recent SRs commissioned by the USPTF and WHO have shown
that earlier treatment of HIV-positive individuals – i.e. at
CD4 count 500 cells/mm3, when individuals are more likely toFig. 5. Screening for HIV: clinical summary of the US Preventive Services Task Force reco
Recommendation Statement, Ann Intern Med 2013, 159: 51–60.be asymptomatic and detected by testing – is associated with
reduced risk for AIDS-related events or death and HIV transmission
to uninfected sexual partners [163,164]. Based on these results,
both the USPTF and WHO issued recommendations in 2013 about
testing (see below). More recently, in 2014, the US Department of
Health and Human Services (HHS) recommended treatment for all
HIV-infected individuals regardless of the patient’s CD4 cell count.
However, the strength of this HHS recommendation varies by
patients’ pre-treatment CD4 cell count, based on available
scientiﬁc evidence; the recommendation is “strong” for
CD4 count <500 cells/mm3, but “moderate” for CD4 count
>500 cells/mm3 [165,166].
On the basis of earlier treatment beneﬁts, and the high
percentage in the US (about 20–25%) of HIV-positive persons
unaware of their positive status, the USPSTF has recommended HIV
“screening” (in actual fact, voluntary testing) of all adolescents and
adults aged 15–65 years at normal risk and younger adolescents
and older adults at increased risk to identify asymptomatic but
infected persons in US settings [167] (Fig. 5). In the absence of
sufﬁcient evidence to determine optimum time intervals for HIV
testing, the USPSTF suggested that “one reasonable approach
would be one-time screening of adolescent and adult patients to
identify persons who are already HIV-positive, with repeated
screening of those who are known to be at risk for HIV infection,
those who are actively engaged in risky behaviors, and those who
live in or receive medical care in a high-prevalence setting” (i.e. a
geographic location or community with an HIV seroprevalence ofmmendation. From V.A. Moyer. Screening for HIV: US Preventive Services Task Force
Table 2
Summary of HIV testing and counselling recommendations in asymptomatic individuals for low-level and concentrated epidemicsa, WHO recommendation.
Who to test When to test
Partners of people with HIV As soon after partner diagnosis as possible
For the negative person in serodiscordant couples, offer re-testing every 6–12 months
Families of index cases (adults and adolescents) As soon as possible after the family member is diagnosed
Key populations (adults and adolescents): people who inject drugs, men
who have sex with men, transgender people and sex workers
Every 6–12 months
Pregnant women At the ﬁrst antenatal care visit
Infants and children <18 months old Early infant diagnosis at 4–6 weeks for all infants whose mothers are living with HIV or if
maternal HIV status is unknown; determine the ﬁnal infant HIV infection status after
18 months and/or when breastfeeding ends
Adapted from Table 5.3 in “Summary of HIV testing and counselling recommendations for low- level and concentrated epidemics”, World Health Organization, consolidated
guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach (June 2013).
a Low-level HIV epidemic: epidemics in which the prevalence of HIV infection has not consistently exceeded 1% in the general population nationally or 5% in any
subpopulation; concentrated HIV epidemic: HIV has spread rapidly in one or more deﬁned subpopulations but is not well established in the general population. Numerical
proxy: HIV prevalence is consistently over 5% in at least one deﬁned subpopulation but is less than 1% among pregnant women in urban areas.
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recommend voluntary testing on the basis of risk assessment (see
Fig. 5 “risk assessment”) in settings where the prevalence of
undiagnosed HIV infections 0.1% [167]. WHO also recommended
HIV testing in asymptomatic individuals to initiate treatment in
HIV-positive individuals at CD4 count 500 cells/mm3 [164]. The
population targeted by the WHO testing recommendation was
deﬁned on the basis of HIV prevalence; in low-prevalence HIV
settings, i.e. <1% in the general population, WHO recommends
(voluntary) HIV testing and counselling to “key populations that
include both vulnerable and most-at-risk populations”, and gives
intervals for testing (Table 2) [164]. In generalized HIV epidemics
(i.e. HIV prevalence 1% in the general population) WHO
recommends (voluntary) HIV testing and counselling to every-
body.
Based on (a) the beneﬁts of timely detection and treatment for
cancer prevention, (b) recommendations for HIV testing in low-
prevalence settings, and (c) ﬁgures obtained in the EU/EEA, the
Working Group on Infections and Vaccination in the European
Code Against Cancer project recommended that: in terms of HIV-
related cancers prevention, individuals in the groups most at risk
for HIV infection and transmission in the EU/EEA (i.e. MSM,
injection drugs users, and migrants from countries or settings with
generalized HIV epidemics) but also individuals from other most
at-risk populations (e.g. sex workers [164]), should be aware of
their HIV status and get treatment if needed. This is in accordance
with the ECDC recommendation, which concluded in their
2014 report that “key populations are the cornerstones of HIV
prevention in most EU/EEA countries” [161]. However, as there is
no clear decrease in the trends of HIV transmission in the EU/EEA,
with heterosexual transmission still remaining the second most
common mode of HIV transmission, the Working Group also
considered that it is important to extend the above recommenda-
tion to all individuals who are or have engaged in risky behaviors
such as having unprotected sex or being injection drug users. Time
intervals for HIV testing should be based on individual risk
assessment and counselling.
5.3. Key point for the general public, healthcare providers and health
policy makers.
In the Q&A section [81], based on the above evidence, the
Working Group on Infections and Vaccination in the European
Code Against Cancer project provides additional information that
would be of particular relevance for all adolescents and adults
interested in learning more about what they could do to lower the
risk of cancer from HIV infection. A key message is: Individuals most at risk for HIV infection are men who have sex
with men, sex workers, injection drug users, people from a
country with high rates of HIV (e.g. sub-Saharan Africa) or
individuals who have unprotected sex without being sure that
their partner is HIV-negative. Individuals most at risk should
consult their healthcare provider to access counselling, testing,
and, if the test is positive, to start treatment without delay. If the
test is positive, delaying treatment allows the virus to spread in
the body and damage the patient’s health, in addition to
increasing the risk of infecting sexual partners. If the test is
negative, the healthcare provider will advise on whether
repeated testing is needed based on the individual’s HIV risk
(see above). The tests used nowadays can usually tell whether a
person has HIV within a month of infection. The most common
tests require only a small amount of blood or saliva.
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